Satsuma Pharmaceuticals Inc - Ordinary Shares
News
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 65th Annual Scientific Meeting
Globe Newswire Oral Presentation: Sustained Efficacy of STS101 DHE Nasal Powder for the Acute Treatment of Migraine: Results from the Phase3 Double-Blind, Randomized, Placebo-Controlled SUMMIT StudyDURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company...\n more…
Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
Benzinga The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.\n more…
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine
Globe Newswire January 2024 PDUFA date expectedIf approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S. Food and Drug Administration (FDA) and International Headache SocietyUnlike ...\n more…
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGTA, CHRA, STSA
PR Newswire SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGTA, CHRA, STSA SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGTA, CHRA, STSA PR Newswire NEW YORK, May 18, 2023 NEW YORK, May 18, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following...\n more…
JonesTrading Sticks to Its Hold Rating for Satsuma Pharmaceuticals (STSA)
TipRanks Financial Blog JonesTrading analyst Sean Kim PhD maintained a Hold rating on Satsuma Pharmaceuticals ( - Research Report) today. The company's shares closed last Friday at $1.05. Kim PhD covers the Healthcare sector, focusing on stocks such as Trevi Therapeutics, Impel Pharmaceuticals, and Ocuphire Pharma.\n more…
SATSUMA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Satsuma Pharmaceutica
Business Wire Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Satsuma Pharmaceuticals, Inc. (Satsuma) (NasdaqGM: STSA) to Shin Nippon Biomedical Laboratories, Ltd. Under the terms of the proposed...\n more…